Cartesian Therapeutics宣布，其采用笛卡尔-8 mRNA与Westgene LNP技术的重症肌无力（MG）临床试验，预计将于2026年下半年正式启动。这项研究标志着该公司在利用先进mRNA平台开发自身免疫性疾病疗法方面迈出了关键一步。试验的推进有望为重症肌无力患者带来新的治疗希望，并进一步验证其专有技术的潜力。
Cartesian Therapeutics宣布，其采用笛卡尔-8 mRNA与Westgene LNP技术的重症肌无力（MG）临床试验，预计将于2026年下半年正式启动。这项研究标志着该公司在利用先进mRNA平台开发自身免疫性疾病疗法方面迈出了关键一步。试验的推进有望为重症肌无力患者带来新的治疗希望，并进一步验证其专有技术的潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.